April 30, 2021
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
TYPE OF SARCOMA: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
DRUG: Selumetinib in Combination with Sirolimus
ACCRUAL STATUS: Recruiting
OVERALL STUDY PRINCIPAL INVESTIGATOR:
AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Health System
Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute
CLINICALTRIALS.GOV IDENTIFIER: NCT03433183
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV
To learn more about this study or to contact the study research staff: